Case Report
BibTex RIS Cite

Abciximab-induced thrombocytopenia: correct management

Year 2022, Volume: 39 Issue: 2, 581 - 583, 18.03.2022

Abstract

Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.

References

  • 1. Nowakowski, K., et al., Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol, 2008. 21(1): p. 100-5.
  • 2. George, J.N. and R.H. Aster, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program, 2009: p. 153-8.
  • 3. Arnold, D.M., et al., A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost, 2013. 11(1): p. 169-76.
  • 4. Park, S., et al., Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Korean Circ J, 2013. 43(8): p. 557-60.
  • 5. Aster, R.H., et al., Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006. 4(3): p. 678-9.
  • 6. Golden, T., et al., Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep, 2017. 2017.
  • 7. Curtis, B.R., et al., Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost, 2004. 2(6): p. 985-92.
  • 8. Aster, R.H. and D.W. Bougie, Drug-induced immune thrombocytopenia. N Engl J Med, 2007. 357(6): p. 580-7.
  • 9. Llevadot, J., S.A. Coulter, and R.P. Giugliano, A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis, 2000. 9(2): p. 175-80.
  • 10. Giupponi, L., et al., Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets, 2015. 26(5): p. 498-500.
  • 11. Arnold, D.M., et al., Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013. 27(3): p. 137-45.
  • 12. Bakchoul, T. and I. Marini, Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program, 2018. 2018(1): p. 576-583.
  • 13. Piątek, Ł., et al., Delayed severe abciximab-induced thrombocytopenia: A case report. Heart Lung, 2016. 45(5): p. 464-5.
Year 2022, Volume: 39 Issue: 2, 581 - 583, 18.03.2022

Abstract

References

  • 1. Nowakowski, K., et al., Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol, 2008. 21(1): p. 100-5.
  • 2. George, J.N. and R.H. Aster, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program, 2009: p. 153-8.
  • 3. Arnold, D.M., et al., A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost, 2013. 11(1): p. 169-76.
  • 4. Park, S., et al., Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Korean Circ J, 2013. 43(8): p. 557-60.
  • 5. Aster, R.H., et al., Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006. 4(3): p. 678-9.
  • 6. Golden, T., et al., Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep, 2017. 2017.
  • 7. Curtis, B.R., et al., Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost, 2004. 2(6): p. 985-92.
  • 8. Aster, R.H. and D.W. Bougie, Drug-induced immune thrombocytopenia. N Engl J Med, 2007. 357(6): p. 580-7.
  • 9. Llevadot, J., S.A. Coulter, and R.P. Giugliano, A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis, 2000. 9(2): p. 175-80.
  • 10. Giupponi, L., et al., Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets, 2015. 26(5): p. 498-500.
  • 11. Arnold, D.M., et al., Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013. 27(3): p. 137-45.
  • 12. Bakchoul, T. and I. Marini, Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program, 2018. 2018(1): p. 576-583.
  • 13. Piątek, Ł., et al., Delayed severe abciximab-induced thrombocytopenia: A case report. Heart Lung, 2016. 45(5): p. 464-5.
There are 13 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Report
Authors

Engin Kelkitli 0000-0001-7342-1760

Aslı Odabaşı Giden 0000-0001-7375-4485

Derya Deniz Kürekçi 0000-0002-0537-9289

Mehmet Turgut 0000-0002-1036-0232

Early Pub Date March 18, 2022
Publication Date March 18, 2022
Submission Date January 28, 2022
Acceptance Date March 17, 2022
Published in Issue Year 2022 Volume: 39 Issue: 2

Cite

APA Kelkitli, E., Odabaşı Giden, A., Deniz Kürekçi, D., Turgut, M. (2022). Abciximab-induced thrombocytopenia: correct management. Journal of Experimental and Clinical Medicine, 39(2), 581-583.
AMA Kelkitli E, Odabaşı Giden A, Deniz Kürekçi D, Turgut M. Abciximab-induced thrombocytopenia: correct management. J. Exp. Clin. Med. March 2022;39(2):581-583.
Chicago Kelkitli, Engin, Aslı Odabaşı Giden, Derya Deniz Kürekçi, and Mehmet Turgut. “Abciximab-Induced Thrombocytopenia: Correct Management”. Journal of Experimental and Clinical Medicine 39, no. 2 (March 2022): 581-83.
EndNote Kelkitli E, Odabaşı Giden A, Deniz Kürekçi D, Turgut M (March 1, 2022) Abciximab-induced thrombocytopenia: correct management. Journal of Experimental and Clinical Medicine 39 2 581–583.
IEEE E. Kelkitli, A. Odabaşı Giden, D. Deniz Kürekçi, and M. Turgut, “Abciximab-induced thrombocytopenia: correct management”, J. Exp. Clin. Med., vol. 39, no. 2, pp. 581–583, 2022.
ISNAD Kelkitli, Engin et al. “Abciximab-Induced Thrombocytopenia: Correct Management”. Journal of Experimental and Clinical Medicine 39/2 (March 2022), 581-583.
JAMA Kelkitli E, Odabaşı Giden A, Deniz Kürekçi D, Turgut M. Abciximab-induced thrombocytopenia: correct management. J. Exp. Clin. Med. 2022;39:581–583.
MLA Kelkitli, Engin et al. “Abciximab-Induced Thrombocytopenia: Correct Management”. Journal of Experimental and Clinical Medicine, vol. 39, no. 2, 2022, pp. 581-3.
Vancouver Kelkitli E, Odabaşı Giden A, Deniz Kürekçi D, Turgut M. Abciximab-induced thrombocytopenia: correct management. J. Exp. Clin. Med. 2022;39(2):581-3.